Bristol Myers Squibb (NYSE: BMY) has selected Houston, Texas, as the location for a new multi-modal manufacturing campus representing approximately $2.3 billion in investment.
The facility will be built at Generation Park in northeast Houston and is designed to accelerate the delivery of next-generation medicines to patients across multiple disease areas.
The announcement marks a significant milestone in BMS’ broader $40 billion commitment to invest in the United States over five years across research, development, technology, and domestic manufacturing.
The campus will span approximately 600,000 square feet and is expected to create nearly 500 skilled permanent jobs once operational.
Roles created will include operations technicians, production specialists, maintenance and engineering professionals, quality control and assurance experts, and site leadership and administration positions.
BMS also expects approximately 2,000 construction and indirect jobs to be generated between 2027 and 2030 while the facility is being built.
Construction is scheduled to begin next year, with the facility expected to come online in 2030, giving the project a multi-year build timeline.
The campus is designed with a modular, multi-modal architecture that allows BMS to add and reconfigure manufacturing capacity as pipeline and commercial needs evolve over time.
Its multi-modal capabilities will allow BMS to manufacture multiple types of medicines, such as small molecules, biologics, and antibody-drug conjugates, supporting production from late development through commercial launch.
The campus is also built with configuration flexibility that anticipates future advances in digital integration and automation, ensuring the site remains at the frontier of biopharmaceutical manufacturing technology.
The $2.3 billion figure represents a notable expansion in project scope from earlier reporting, which had pegged the investment closer to $1 billion when BMS first filed documents with the state of Texas in May.
Those initial filings described a $1 billion, 600,000-square-foot complex with an option to expand, located within the Generation Park Management District in northeast Houston.
Texas Governor Greg Abbott confirmed that BMS has been awarded a $4.89 million Texas Enterprise Fund grant to support the project’s development and job creation goals.
The campus is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation programme, known as JETI, adding further state-level backing to the investment.
BMS selected Texas and Generation Park following an extensive, competitive evaluation of multiple markets across the Central and Eastern United States, weighing workforce strength, incentives, and infrastructure.
The announcement adds to a growing concentration of pharmaceutical investment at Generation Park, where Eli Lilly previously committed more than $6.5 billion to build a facility focused on domestic small-molecule medicine production.
Together, the two projects represent at least $8.8 billion in announced pharmaceutical manufacturing investment at the Generation Park site, underscoring its emergence as a major life sciences hub.